Tailored antibody-drug conjugate offers hope for aggressive breast cancer

FHS
May 22, 2024
3:48 am

Scientists have used breast cancer cells’ weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumors.

Hiring in the US pharma industry drop by 25% in Q3 2023

Notably, Management Occupations jobs accounted for a 20% share of the US pharma industry new job postings in Q3 2023, down by 41% over the

October 19, 2023

Medartis launches senior convertible bond offering in a private placement of approximately CHF 115 million due 2031 – Biotech Investments

Medartis Holding AG / Key word(s): Financing/Issue of Debt 03-Apr-2024 / 17:43 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

April 5, 2024

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant | Psychedelic Invest

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of psilocybin-based therapeutics, today provided an update on its

October 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.